A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours

BACKGROUND: We aimed to assess the safety, tolerability and pharmacokinetics of a novel anti-angiogenic peptide. METHODS: We used an open-label, multicentre, dose-escalation Phase I trial design in patients with solid tumours. ALM201 was administered subcutaneously once daily for 5 days every week i...

Descripción completa

Detalles Bibliográficos
Autores principales: El Helali, Aya, Plummer, Ruth, Jayson, Gordon C., Coyle, Vicky M., Drew, Yvette, Mescallado, Nerissa, Harris, Noor, Clamp, Andrew R., McCann, Janine, Swaisland, Helen, Kennedy, Richard D., Cranston, Aaron N., Wilson, Richard H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276671/
https://www.ncbi.nlm.nih.gov/pubmed/35568736
http://dx.doi.org/10.1038/s41416-022-01780-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276671/
https://www.ncbi.nlm.nih.gov/pubmed/35568736
http://dx.doi.org/10.1038/s41416-022-01780-z

Ejemplares similares